MRUS vs. MOR, MLTX, ACAD, SMMT, ARWR, PTCT, CORT, INDV, RYTM, and JANX
Should you be buying Merus stock or one of its competitors? The main competitors of Merus include MorphoSys (MOR), MoonLake Immunotherapeutics (MLTX), ACADIA Pharmaceuticals (ACAD), Summit Therapeutics (SMMT), Arrowhead Pharmaceuticals (ARWR), PTC Therapeutics (PTCT), Corcept Therapeutics (CORT), Indivior (INDV), Rhythm Pharmaceuticals (RYTM), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical preparations" industry.
Merus (NASDAQ:MRUS) and MorphoSys (NASDAQ:MOR) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, community ranking, earnings and risk.
Merus has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.
Merus has higher earnings, but lower revenue than MorphoSys. Merus is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.
In the previous week, Merus and Merus both had 2 articles in the media. Merus' average media sentiment score of 0.06 beat MorphoSys' score of -0.46 indicating that Merus is being referred to more favorably in the media.
Merus received 298 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 65.52% of users gave Merus an outperform vote while only 38.46% of users gave MorphoSys an outperform vote.
96.1% of Merus shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 4.6% of Merus shares are owned by insiders. Comparatively, 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
MorphoSys has a net margin of -226.79% compared to Merus' net margin of -352.56%. Merus' return on equity of -50.61% beat MorphoSys' return on equity.
Merus currently has a consensus target price of $56.33, indicating a potential upside of 15.60%. MorphoSys has a consensus target price of $11.78, indicating a potential downside of 34.34%. Given Merus' stronger consensus rating and higher possible upside, analysts plainly believe Merus is more favorable than MorphoSys.
Summary
Merus beats MorphoSys on 12 of the 17 factors compared between the two stocks.
Get Merus News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
